PALO ALTO, Calif.–(EON: Enhanced Online News)–CollabRx, the company that leverages information technology to inform personalized cancer treatment planning, announces the release of a Targeted Therapy Finder application (“app”) for lung cancer. Targeted Therapy Finder apps are dynamically updated online resources that enable physicians and patients to identify diagnostic tests and clinical trials associated with therapies that “target” the unique genetic profiles of patients’ tumors. The Targeted Therapy Finder – Lung Cancer app builds on the success of the first such app released by CollabRx earlier this year for melanoma. The melanoma app was created in partnership with the American Society of Clinical Oncology (ASCO) as a first-of-its kind resource for cancer patients and physicians.

Lung cancer is one of the most common cancer types in the U.S. (and worldwide) and is by far the most lethal, resulting in an estimated 150,000 deaths in 2011, according to the American Cancer Society. Lung cancer is responsible for more cancer-related deaths in women than breast and ovarian cancers combined. Some forms of the disease can be treated with targeted therapies (particularly for women), and CollabRx’ Targeted Therapy Finder app was developed to bring this knowledge to the people who need it most.

The Targeted Therapy Finder – Lung Cancer is available now at www.collabrx.com/lung. The app allows physicians and patients to input information about their disease – including the stage of progression, type of lung cancer histology, status of genetic mutations known to have implications for treatment, and sites of metastasis, if any. It then provides personalized treatment-related recommendations, based on peer-reviewed medical and scientific content, that may be of use to the patient and physician, such as identification of potential drugs, diagnostics and clinical trials that may have utility in the specific form of lung cancer selected. The app content is kept up-to-date by a team of scientists and top cancer experts, such as Ravi Salgia, MD, PhD, a professor of Medicine at the University of Chicago, who continually monitor the scientific literature to stay abreast of new developments in the field.